Technical Analysis for IRWD - Ironwood Pharmaceuti

Grade Last Price % Change Price Change
grade C 12.53 4.24% 0.5100
IRWD closed up 4.24 percent on Tuesday, January 21, 2020, on 85 percent of normal volume. The bulls were able to push the stock to a new 52-week high.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical IRWD trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
New 52 Week High Strength 0.00%
Gapped Up Strength 0.00%
New 52 Week Closing High Bullish 4.24%
New 52 Week High Strength 4.24%
Gapped Up Strength 4.24%
New 52 Week Closing Low Bearish 43.20%
New 52 Week Closing High Bullish 41.10%
New 52 Week Low Weakness 41.10%
Older signals for IRWD ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. The company pipeline products also include olinciguat, an oral and once-daily vascular sGC stimulator, which is in Phase II trials for the treatment of patients suffering from sickle cell diseases; praliciguat, an oral, once daily systemic sGC stimulator that is in Phase II trials for the treatment of heart failure and for diabetic nephropathy; IW 6463, a central nervous system penetrant oral sGC stimulator in clinical development for serious neurodegenerative diseases; and two organ targeted programs for the treatment of liver and lung. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Medical Specialties European Union Heart Failure Gastroenterology Constipation Diarrhea Irritable Bowel Syndrome Diabetic Nephropathy Treatment Of Heart Failure Allergan

Is IRWD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 12.92
52 Week Low 8.4
Average Volume 1,690,920
200-Day Moving Average 0.0000
50-Day Moving Average 0.0000
20-Day Moving Average 0.0000
10-Day Moving Average 0.0000
Average True Range 0.0000
ADX 0.0
+DI 0.0000
-DI 0.0000
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0000
Lower Bollinger Band 0.0000
Percent B (%b) 0.0
BandWidth 0.0000
MACD Line 0.0000
MACD Signal Line 0.0000
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.2064
Resistance 3 (R3) 13.2612 13.0906 13.0936
Resistance 2 (R2) 13.0906 12.9184 13.0632 13.0560
Resistance 1 (R1) 12.8103 12.8119 12.9505 12.7555 13.0185
Pivot Point 12.6397 12.6397 12.7098 12.6123 12.6397
Support 1 (S1) 12.3594 12.4675 12.4996 12.3046 12.0415
Support 2 (S2) 12.1888 12.3610 12.1614 12.0040
Support 3 (S3) 11.9085 12.1888 11.9664
Support 4 (S4) 11.8537